FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740782649> ?p ?o ?g. }

• W2740782649 abstract "E7449 is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). Preclinical studies reported antitumor activity of single-agent E7449 in BRCA-deficient in vivo models. An open-label, multicenter, phase 1 study was completed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of single-agent E7449. The MTD was determined to be 600 mg/day (n = 8). Treatment-emergent adverse events led to drug withdrawal in 1 patient and dose interruption in 2 patients at this dose level. E7449 treatment at the MTD was associated with substantial and sustained dose-dependent PARP inhibition. The overall response rate was 7.1% (2 confirmed partial responses [PR]) and durable stable disease (≥23 weeks) was observed in 21.4% of patients. Here we report additional PD and PK results from this trial. Patients in this study (N=28) were ≥ 18 years and had measurable, confirmed, advanced solid tumors or B-cell lymphoma that had progressed after approved treatment. Patients received E7449 at 50, 100, 200, 600, or 800 mg/day. Food effect was examined in an MTD expansion cohort. PD assessments included measurement of PARP activity and comet assay to determine the extent of DNA damage. In the food-effect cohort (n=13), PARP inhibition (up to 90%) was sustained during treatment with the MTD of E7449 600 mg/day up to 24 hours post-dose. Peak E7449 plasma concentrations were delayed by 2 hours in fed patients compared with fasted patients. In the PK/PD analysis set, peak plasma concentrations of E7449 were observed at 2 hours following a single dose, and coincided with the lowest levels of poly (ADP-ribose) (PAR; up to 90% inhibition). Of note, while E7449 exposure was highest at the 800 mg dose, the lowest PAR levels were observed at the 600 mg dose. At the time of observed responses, the 2 patients with confirmed PR demonstrated greater than 90% PAR inhibition from baseline. E7449 did not cause a change in the level of DNA damage that could be detected by the comet assay. DNA damage levels remained similar to the damage seen in healthy donors. No significant changes in percent DNA in the electrophoresis comet tail by dose or E7449 plasma concentration were observed. In conclusion, continuous E7449 dosing at 600 mg/day was associated with sustained PARP inhibition. Dose-dependent PARP inhibition was observed and the greatest PARP inhibition occurred at the 600 mg dose. Peak E7449 plasma concentration appeared to coincide with maximal PARP inhibition. These results support E7449 dosing at 600 mg/day. Citation Format: Pallavi Sachdev, Shannon McGrath, Robert Shumaker, Jagadeesh Aluri, Claudio Savulsky. Pharmacodynamic and pharmacokinetic relationship of single agent E7449 in patients with advanced solid tumors or B-cell malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5050. doi:10.1158/1538-7445.AM2017-5050" @default.
• W2740782649 created "2017-08-08" @default.
• W2740782649 creator A5004534666 @default.
• W2740782649 creator A5024967501 @default.
• W2740782649 creator A5056514511 @default.
• W2740782649 creator A5083205599 @default.
• W2740782649 creator A5085639542 @default.
• W2740782649 date "2017-07-01" @default.
• W2740782649 modified "2023-09-27" @default.
• W2740782649 title "Abstract 5050: Pharmacodynamic and pharmacokinetic relationship of single agent E7449 in patients with advanced solid tumors or B-cell malignancies" @default.
• W2740782649 doi "https://doi.org/10.1158/1538-7445.am2017-5050" @default.
• W2740782649 hasPublicationYear "2017" @default.
• W2740782649 type Work @default.
• W2740782649 sameAs 2740782649 @default.
• W2740782649 citedByCount "0" @default.
• W2740782649 crossrefType "proceedings-article" @default.
• W2740782649 hasAuthorship W2740782649A5004534666 @default.
• W2740782649 hasAuthorship W2740782649A5024967501 @default.
• W2740782649 hasAuthorship W2740782649A5056514511 @default.
• W2740782649 hasAuthorship W2740782649A5083205599 @default.
• W2740782649 hasAuthorship W2740782649A5085639542 @default.
• W2740782649 hasConcept C104317684 @default.
• W2740782649 hasConcept C111113717 @default.
• W2740782649 hasConcept C112705442 @default.
• W2740782649 hasConcept C126322002 @default.
• W2740782649 hasConcept C143998085 @default.
• W2740782649 hasConcept C150903083 @default.
• W2740782649 hasConcept C182979987 @default.
• W2740782649 hasConcept C185592680 @default.
• W2740782649 hasConcept C197934379 @default.
• W2740782649 hasConcept C207001950 @default.
• W2740782649 hasConcept C22979827 @default.
• W2740782649 hasConcept C2779138821 @default.
• W2740782649 hasConcept C2779338263 @default.
• W2740782649 hasConcept C55493867 @default.
• W2740782649 hasConcept C71924100 @default.
• W2740782649 hasConcept C82381507 @default.
• W2740782649 hasConcept C86803240 @default.
• W2740782649 hasConcept C90924648 @default.
• W2740782649 hasConcept C98274493 @default.
• W2740782649 hasConceptScore W2740782649C104317684 @default.
• W2740782649 hasConceptScore W2740782649C111113717 @default.
• W2740782649 hasConceptScore W2740782649C112705442 @default.
• W2740782649 hasConceptScore W2740782649C126322002 @default.
• W2740782649 hasConceptScore W2740782649C143998085 @default.
• W2740782649 hasConceptScore W2740782649C150903083 @default.
• W2740782649 hasConceptScore W2740782649C182979987 @default.
• W2740782649 hasConceptScore W2740782649C185592680 @default.
• W2740782649 hasConceptScore W2740782649C197934379 @default.
• W2740782649 hasConceptScore W2740782649C207001950 @default.
• W2740782649 hasConceptScore W2740782649C22979827 @default.
• W2740782649 hasConceptScore W2740782649C2779138821 @default.
• W2740782649 hasConceptScore W2740782649C2779338263 @default.
• W2740782649 hasConceptScore W2740782649C55493867 @default.
• W2740782649 hasConceptScore W2740782649C71924100 @default.
• W2740782649 hasConceptScore W2740782649C82381507 @default.
• W2740782649 hasConceptScore W2740782649C86803240 @default.
• W2740782649 hasConceptScore W2740782649C90924648 @default.
• W2740782649 hasConceptScore W2740782649C98274493 @default.
• W2740782649 hasLocation W27407826491 @default.
• W2740782649 hasOpenAccess W2740782649 @default.
• W2740782649 hasPrimaryLocation W27407826491 @default.
• W2740782649 hasRelatedWork W1978219119 @default.
• W2740782649 hasRelatedWork W1996198321 @default.
• W2740782649 hasRelatedWork W2025427832 @default.
• W2740782649 hasRelatedWork W2033618667 @default.
• W2740782649 hasRelatedWork W2040146091 @default.
• W2740782649 hasRelatedWork W2053717084 @default.
• W2740782649 hasRelatedWork W2321772901 @default.
• W2740782649 hasRelatedWork W2325082608 @default.
• W2740782649 hasRelatedWork W2398845841 @default.
• W2740782649 hasRelatedWork W2419628299 @default.
• W2740782649 hasRelatedWork W2474545869 @default.
• W2740782649 hasRelatedWork W2572796572 @default.
• W2740782649 hasRelatedWork W2586240666 @default.
• W2740782649 hasRelatedWork W2740563488 @default.
• W2740782649 hasRelatedWork W2784043644 @default.
• W2740782649 hasRelatedWork W2979201149 @default.
• W2740782649 hasRelatedWork W3030168959 @default.
• W2740782649 hasRelatedWork W3096705707 @default.
• W2740782649 hasRelatedWork W3181346462 @default.
• W2740782649 hasRelatedWork W54091601 @default.
• W2740782649 isParatext "false" @default.
• W2740782649 isRetracted "false" @default.
• W2740782649 magId "2740782649" @default.
• W2740782649 workType "article" @default.